Mathias Haarhaus (@mathaarhaus) header
Mathias Haarhaus (@mathaarhaus) profile picture

Nephrologist, striving to improve treatment and prevention of CKD-MBD, cardiovascular complications and mortality.

Stockholm, Sverige
Joined May 2017
Photo by Mathias Haarhaus (@mathaarhaus)Photo by Mathias Haarhaus (@mathaarhaus)Photo by Mathias Haarhaus (@mathaarhaus)
🏆Congratulations @mjlloretcora !!!! #bestabstract award in the 6º EUROD Winter Meeting #CKDMBD @ERAkidney @SENefrologia @nefrocat @senjoven
2
6
20
1,649
Amazing talk by @LucileFigueres on calcium and magnésium in CKD during the EUROD meeting in Leuven! #EUROD @FiliereOSCAR @FiliereORKiD
3
10
952
1
1
5
241
Advanced CKD no longer an obstacle for osteoporosis treatment? See new recommendations by IOF & ERA-EDTA: Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism | SpringerLink link.springer.com/article/10…
3
1
Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment - Kidney International. The underlying cause may determine the association of low bone turnover with outcome, which is not always unfafourable. kidney-international.org/art…
1
1
Fresh from the press: the joint statement of IOF and ERA-EDTA on management of osteoporosis in advanced CKD.
ASN in beautiful Washington D.C. Proud team presenting exciting new data on a strong association of serum ALP with cognitive impairment (R^2=0.96) in the baseline assessment of BETonMACE
1
3
1
8
First report ever of a clinical intervention that lowers alkaline phosphatase and improves cardiovascular outcome in patients with CVD. Is this the humble start of a new therapeutic paradigm: targeting ALP for cardiovascular risk reduction?
Joint effort to improve outcome for CKD patients. nitter.cf/kamkalantar/status/864…
Nature Reviews Nephrol hot: Alkaline Phosphatase (#ALP) strikes back in CKD a novel treatment target for CV disease nature.com/nrneph/journal/va…
1
What's hot in CKD? Nature Rev Nephrol: Targeting ALP to improve survival.
1
1